NEW YORK (GenomeWeb News) – Empire Genomics today announced it has licensed a genomic biomarker from Cornell University for the development of a test to diagnose and determine treatment of patients with neuroendocrine prostate cancer, or NEPC.

Empire and Cornell will partner on developing a commercial grade assay and Empire plans to launch the NEPC test later this year. Empire also plans to seek a pharmaceutical partner to use the assay to accelerate patient stratification in clinical trials, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.